Our programme office

Our programme office provides support and encourages collaboration across our experimental cancer medicine centres (ECMC) network.

Contact us at ecmcadmin@cancer.org.uk

Supporting our clinical network

The programme office facilitates set up and delivery of clinical research studies across our 29 centres.

We act as a single-entry point to our network – developing partnerships with sponsors and connecting them with the right sites to run their clinical trial. We also support our centres with training, resource development and through our network groups and forums.

The programme office supports the three pillars of our strategy:

  • accelerating innovative translational research

  • delivering globally competitive research

  • increasing patient centred and accessible research

Meet the team

Graham Cadwallader.

Graham Cadwallader

Head of Clinical Research, Cancer Research UK

Karolin Kroese.

Karolin Kroese

ECMC Programme Lead

Image of Gary Middleton.

Gary Middleton

ECMC Network Lead

Catherine Cowell.

Catherine Cowell

Translational Research Lead

Sharan Sandhu.

Sharan Sandhu

Operations and Delivery Lead

Hannah Brown.

Hannah Brown

Engagement and Impact Lead

Jemma Mitchell.

Jemma Mitchell

Paediatric Research Manager

Priyanka Kiritharan.

Priyanka Kiritharan

Research Manager

Neil Bhattacherjee.

Neil Bhattacherjee

Project Manager

Ravinder Nizzer.

Ravinder Nizzer

Project Manager

Talia Macauley Kelly.

Talia Macauley Kelly

Paediatric Engagement Manager

Who we work with

Businessman and woman having a meeting in a coffee shop, discussing work.

Industry and partners

We are a centralised platform for commercial partners to launch trials quickly with access to expert teams, sites and processes.

Research nurse demonstrating medical equipment usage to other staff.

Our network

Our centres have unique research strengths and work collaboratively to share data, practices, and staff training.

Several people sat in discussion.

Patients and public

We support patient centric early-phase trials. Patient and public involvement shapes how we do this.

You might also be interested in